<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368039</url>
  </required_header>
  <id_info>
    <org_study_id>2019H0424</org_study_id>
    <nct_id>NCT04368039</nct_id>
  </id_info>
  <brief_title>Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis</brief_title>
  <official_title>Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicholas Breitborde</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-blind, randomized controlled trial of normobaric oxygen therapy among individuals with
      first-episode psychosis: Effects on symptomatology and cognition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Functional deficits in prefrontal, limbic, and temporal regions of the brain are
      well-documented among individuals with psychotic disorders. Mitochondrial dysfunction may
      contribute to such pathology, and effective functioning of mitochondrial activity in the
      brain in dependent on a sufficient supply of oxygen. These data suggest that oxygen therapy
      may improve symptoms in individuals with psychosis. This small pilot study will test this
      hypothesis.

      Individuals with first-episode psychosis will be randomized to receive either (i) 4 weeks of
      nightly normobaric oxygen therapy (40% FiO2) or (ii) 4 weeks of a placebo condition utilizing
      room air oxygen levels (21% FiO2). Participants will be blinded to what condition they
      receive. Both conditions will be delivered via nasal cannula connected to oxygen
      concentrators at five liters per minute (lpm), and participants will be instructed to
      complete the intervention overnight while sleeping. At the end of the 4 week period, all
      individuals will receive an additional 4 weeks of unblinded (i.e., &quot;open label&quot;) nightly
      normobaric oxygen therapy (40% FiO2). Study assessments will be completed at (i) enrollment;
      (ii) 4 weeks after enrollment, and (iii) 8 weeks after enrollment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 7, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cognitive functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the MATRICS Consensus Cognitive Battery (MCCB).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on WHO Quality of Life Scale Brief (WHOQOL-BREF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in social functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Global Functioning: Social</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in role functioning</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Global Functioning: Role</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in health-related quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the RAND 36-Item Health Survey.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in suicidality</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Columbia Suicide Severity Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in substance use severity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the HABITS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in service utilization</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Modified Service Use and Resources Form for Schizophrenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Pittsburgh Sleep Quality Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in medication adherence</measure>
    <time_frame>4 weeks</time_frame>
    <description>Change in scores on the Medication Adherence rating Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Psychosis</condition>
  <condition>Schizophrenia</condition>
  <condition>First-episode Psychosis</condition>
  <arm_group>
    <arm_group_label>Normobaric Oxygen Therapy (40% FiO2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of nightly normobaric oxygen therapy (40% FiO2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Condition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 weeks of a placebo condition utilizing room air oxygen levels (21% FiO2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Normobaric Oxygen</intervention_name>
    <description>40% FiO2 for 4 weeks</description>
    <arm_group_label>Normobaric Oxygen Therapy (40% FiO2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>21% FiO2 for 4 weeks</description>
    <arm_group_label>Placebo Condition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Diagnosis of a schizophrenia-spectrum disorder or mood disorder with psychotic
             features as determined using the Structured Clinical Interview for the DSM-5.

          -  Less than 5 years since the onset of frank psychotic symptoms as determined using the
             Symptom Onset in Schizophrenia Inventory .

          -  No evidence of a pre-existing intellectual disability defined as a premorbid IQ &gt;70 as
             estimated using the Reading subtest of the Wide Range Achievement Test-4.

          -  Ages 15-35

          -  Non-smoker for past six months

          -  Absence of suicidal ideation or behavior over the past month as assessed by the
             Columbia Suicide Severity Rating Scale

          -  The American Association for Respiratory Care notes that &quot;no absolute
             contraindications to oxygen therapy exist when indications [for oxygen therapy] are
             present.&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicholas Breitborde, PhD</last_name>
    <phone>(614) 685-6052</phone>
    <email>nicholas.breitborde@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harding Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Breitborde, PhD</last_name>
      <phone>614-685-6052</phone>
      <email>nicholas.breitborde@osumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hill K, Mann L, Laws KR, Stephenson CM, Nimmo-Smith I, McKenna PJ. Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies. Acta Psychiatr Scand. 2004 Oct;110(4):243-56.</citation>
    <PMID>15352925</PMID>
  </reference>
  <reference>
    <citation>Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol Psychiatry. 2004 Apr 1;55(7):676-84.</citation>
    <PMID>15038995</PMID>
  </reference>
  <reference>
    <citation>Kann O, Kov√°cs R. Mitochondria and neuronal activity. Am J Physiol Cell Physiol. 2007 Feb;292(2):C641-57. Epub 2006 Nov 8. Review.</citation>
    <PMID>17092996</PMID>
  </reference>
  <reference>
    <citation>Bloch Y, Applebaum J, Osher Y, Amar S, Azab AN, Agam G, Belmaker RH, Bersudsky Y. Normobaric hyperoxia treatment of schizophrenia. J Clin Psychopharmacol. 2012 Aug;32(4):525-30. doi: 10.1097/JCP.0b013e31825d70b8.</citation>
    <PMID>22722511</PMID>
  </reference>
  <reference>
    <citation>First, M.B., et al., Structured Clinical Interview for DSM-5-Research Version2015, Arlington, VA: American Psychiatric Association.</citation>
  </reference>
  <reference>
    <citation>Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA. Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res. 2000 Jul 7;44(1):1-10.</citation>
    <PMID>10867307</PMID>
  </reference>
  <reference>
    <citation>Wilkinson, G.S. and G.J. Robertson, Wide Range Achievement Test (WRAT4)2006, Lutz, FL: PAR, Inc.</citation>
  </reference>
  <reference>
    <citation>Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011 Dec;168(12):1266-77. doi: 10.1176/appi.ajp.2011.10111704.</citation>
    <PMID>22193671</PMID>
  </reference>
  <reference>
    <citation>AARC. AARC clinical practice guideline. Oxygen therapy in the home or alternate site health care facility--2007 revision &amp; update. Respir Care. 2007 Aug;52(8):1063-8.</citation>
    <PMID>17715561</PMID>
  </reference>
  <reference>
    <citation>Tandon R. Schizophrenia and other psychotic disorders in DSM-5. Clin Schizophr Relat Psychoses. 2013 Apr;7(1):16-9. doi: 10.3371/CSRP.TA.032513.</citation>
    <PMID>23538289</PMID>
  </reference>
  <reference>
    <citation>Auther, A., C. Smith, and B. Cornblatt, Global Functioning: Social Scale (GF: Social). Glen Oaks, NY: Zucker-Hillside Hospital, 2006.</citation>
  </reference>
  <reference>
    <citation>Niendam, T., et al., Global Functioning: Role Scale (GF: Role). Los Angeles, CA: University of California, Los Angeles, 2006.</citation>
  </reference>
  <reference>
    <citation>Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006 Dec;163(12):2080-9.</citation>
    <PMID>17151158</PMID>
  </reference>
  <reference>
    <citation>Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese FJ 3rd, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008 Feb;165(2):203-13. doi: 10.1176/appi.ajp.2007.07010042. Epub 2008 Jan 2.</citation>
    <PMID>18172019</PMID>
  </reference>
  <reference>
    <citation>Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8.</citation>
    <PMID>9626712</PMID>
  </reference>
  <reference>
    <citation>Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res. 2000 May 5;42(3):241-7.</citation>
    <PMID>10785582</PMID>
  </reference>
  <reference>
    <citation>Hays, R.D., S. Prince-Embury, and H.Y. Chen, RAND-36 Health Status Inventory1998, San Antonio, TX: The Psychological Corporation.</citation>
  </reference>
  <reference>
    <citation>Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22(2):343-81.</citation>
    <PMID>3774930</PMID>
  </reference>
  <reference>
    <citation>Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213.</citation>
    <PMID>2748771</PMID>
  </reference>
  <reference>
    <citation>Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005 Mar;62(3):247-53.</citation>
    <PMID>15753237</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Nicholas Breitborde</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>psychosis</keyword>
  <keyword>treatment</keyword>
  <keyword>normobaric hyperoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

